

ASX Announcement

Appendix 3Y - Dr Daniel Tillett

11 March 2021 – Race Oncology ASX RAC provides the attached Appendix 3Y, following the exercise of 4,250,000 \$0.099 cent 31 August 2021 Options by Dr Daniel Tillett.

Dr Daniel Tillett, Chief Scientific Officer and Executive Director has advised that; *"I chose to exercise my 4.25 million 9.9c options early for tax planning purposes. I have not sold any Race shares to fund the conversion, nor do I intend to sell any shares in the immediate or medium-term future. I believe Race Oncology has an extraordinary opportunity with Bisantrene and I look forward to seeing our clinical trial plans progress."*

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase II/III cancer drug called Bisantrene.

Bisantrene is a potent inhibitor of the Fat mass and obesity associated (FTO) protein. Over-expression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Bisantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers. The Company also has compelling clinical data for the use of Bisantrene as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), breast and ovarian cancers and is investigating its use in these areas.

Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy for the clinical development of Bisantrene.

See more at www.raceoncology.com.

Release authorised by:

Phil Lynch, CEO/MD on behalf
of the Race Board of Directors
phillip.lynch@raceoncology.com

Media contact:

Jane Lowe
+61 411 117 774
jane.lowe@irdepartment.com.au

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

| | |
|-----------------------|------------------------------|
| Name of entity | Race Oncology Limited |
| ABN | 61 149 318 749 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|-------------------------|
| Name of Director | Daniel Tillett |
| Date of last notice | 30 November 2020 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|--|
| Direct or indirect interest | Direct |
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | N/A |
| Date of change | 10 March 2021 |
| No. of securities held prior to change | 9,200,000 – fully paid ordinary shares 4,250,000 – options exercisable at \$0.099, expiring 31/08/2021 2,500,000 – options exercisable at \$0.19, expiring 25/11/2022 2,000,000 – options exercisable at \$2.65, expiring 29/11/2025 and subject to vesting conditions. |
| Class | Fully paid ordinary shares Options exercisable at \$0.099, expiring 31/08/2021 |
| Number acquired | 4,250,000 fully paid ordinary shares |
| Number disposed | 4,250,000 options exercisable at \$0.099, expiring 31/08/2021 |
| Value/Consideration includes brokerage/gst Note: If consideration is non-cash, provide details and estimated valuation | \$420,750 |

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

| | |
|---|---|
| No. of securities held after change | 13,450,000 – fully paid ordinary shares 2,500,000 – options exercisable at \$0.19, expiring 25/11/2022 2,000,000 – options exercisable at \$2.65, expiring 29/11/2025 and subject to vesting conditions. |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Exercise of 4,250,000 options exercisable at \$0.099, expiring 31/08/2021 |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|-----|
| Detail of contract | N/A |
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| Interest after change | N/A |

Part 3 – ⁺Closed period

| | |
|---|-----|
| Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required? | No. |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

⁺ See chapter 19 for defined terms.